abacavir sulfate / dolutegravir sodium / lamivudine

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR) for Triumeq. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Triumeq.

For practical information about using Triumeq, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 11/10/2019

Authorisation details

Product details
Agency product number
Active substance
  • abacavir sulfate
  • dolutegravir sodium
  • lamivudine
International non-proprietary name (INN) or common name
abacavir sulfate / dolutegravir sodium / lamivudine
Therapeutic area (MeSH)
HIV Infections
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
ViiV Healthcare BV
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Huis ter Heideweg 62
3705 LZ Zeist
The Netherlands

Product information

20/06/2019 Triumeq - EMEA/H/C/002754 - R/0063


Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Antivirals for systemic use

Therapeutic indication

Triumeq is indicated for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age weighing at least 40 kg.

Before initiating treatment with abacavir-containing products, screening for carriage of the HLA-B*5701 allele should be performed in any HIV-infected patient, irrespective of racial origin. Abacavir should not be used in patients known to carry the HLA-B*5701 allele.

Assessment history

How useful was this page?

Add your rating
4 ratings